<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1904">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05136378</url>
  </required_header>
  <id_info>
    <org_study_id>2020ZSLC56</org_study_id>
    <secondary_id>B2021-447R</secondary_id>
    <nct_id>NCT05136378</nct_id>
  </id_info>
  <brief_title>Selenious Yeast in CLL Patients w/o Indication of Chemotherapy</brief_title>
  <official_title>Administration of Selenious Yeast Tablets in Chronic Lymphocytic Leukemia Patients Without Indication of Chemotherapy: A Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Changzheng Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of Selenious Yeast&#xD;
      Tablets in Chronic Lymphocytic Leukemia Patients without Indication of Chemotherapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A large portion of CLL patients has no indications of chemotherapy when diagnosed. In&#xD;
      patients with CLL, the mean serum selenium levels are lower than normal. There is a&#xD;
      correlation between the selenium level and the clinical stage. We discovered that sodium&#xD;
      selenite inhibited the expression of CXCL-1 and restored the defective necroptotic pathway of&#xD;
      CLL cells together with TNF-α and z-VAD in vitro. The purpose of this study is to evaluate&#xD;
      the safety and effectiveness of Selenious Yeast Tablets in preventing CLL patients without&#xD;
      indication of chemotherapy from disease development.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-year DPR</measure>
    <time_frame>2 years from enrollment</time_frame>
    <description>2-year Disease Progression Rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Decrease rate of Lymphocyte</measure>
    <time_frame>2 years from enrollment</time_frame>
    <description>Decrease rate of peripheral lymphocyte counts</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Selenium Concentration, Serum</measure>
    <time_frame>Enrollment, 1 Month(from enrollment), 3 Months, 6 Months</time_frame>
    <description>Serum selenium concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>Enrollment, 1 Month (from enrollment), 3 Months, 6 Months</time_frame>
    <description>safety profile of the subjects from enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival (PFS)</measure>
    <time_frame>2 years from enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>2 years from enrollment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Lymphocytic Leukemia Stage A(0)</condition>
  <condition>Chronic Lymphocytic Leukemia Stage A(I)</condition>
  <condition>Chronic Lymphocytic Leukemia Stage A(II)</condition>
  <condition>Chronic Lymphocytic Leukaemia Stage B(I)</condition>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Wait and Watch.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose Selenious Yeast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receive 200μg Selenious Yeast per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Selenious Yeast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receive 400μg Selenious Yeast per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Dose Selenious Yeast Tablets</intervention_name>
    <description>Low dose of Selenious Yeast Tablets</description>
    <arm_group_label>Low Dose Selenious Yeast</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Dose Selenious Yeast Tablets</intervention_name>
    <description>High Dose Selenious Yeast Tablets</description>
    <arm_group_label>High Dose Selenious Yeast</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -&#xD;
&#xD;
        Newly diagnosed CLL/small lymphocytic lymphoma (SLL) that meets criteria below:&#xD;
&#xD;
          1. Newly diagnosed (&lt; 12 months from pre-registration on this study) CLL according to the&#xD;
             National Cancer Institute (NCI) criteria or SLL according to the World Health&#xD;
             Organization (WHO) criteria; this includes previous documentation of: Biopsy-proven&#xD;
             small lymphocytic lymphoma OR Diagnosis of CLL according to NCI working group criteria&#xD;
             as evidenced by all of the following: Peripheral blood lymphocyte count of &gt;&#xD;
             5,000/mm^3; if present, prolymphocytes should be &lt; 55% AND Immunophenotyping&#xD;
             consistent with CLL defined as:The predominant population of lymphocytes share both&#xD;
             B-cell antigens (cluster of differentiation [CD]19, CD20, or CD23) as well as CD5 in&#xD;
             the absence of other pan-T-cell markers (CD3, CD2, etc.) Dim surface immunoglobulin&#xD;
             expression Restricted surface kappa or lambda light chain expression Before diagnosing&#xD;
             CLL or SLL, mantle cell lymphoma must be excluded by demonstrating a negative&#xD;
             fluorescent in situ hybridization (FISH) analysis for t(11;14)(immunoglobulin H&#xD;
             [IgH]/cyclin D 1 [CCND1]) on peripheral blood or tissue biopsy or negative&#xD;
             immunohistochemical stains for cyclin D1 on involved tissue biopsy&#xD;
&#xD;
          2. Rai stage 0 or 1&#xD;
&#xD;
          3. Previously untreated&#xD;
&#xD;
          4. Asymptomatic with the plan for observation(NOT meet iwCLL indication of chemotherapy)&#xD;
&#xD;
          5. Life expectancy of at least 12 months&#xD;
&#xD;
          6. Willing to provide tissue for correlative research purpose&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Concentration of serum Se exceed the normal range&#xD;
&#xD;
          2. Active other malignancy requiring treatment that would interfere with the assessments&#xD;
             of this study&#xD;
&#xD;
          3. Hepatitis B or C&#xD;
&#xD;
          4. Autoimmune disease history&#xD;
&#xD;
          5. Organ transplant recipients need to receive drug therapy&#xD;
&#xD;
          6. Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris,&#xD;
             uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would&#xD;
             limit compliance with study requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zheng Wei, M.D.</last_name>
      <phone>021-64041990</phone>
      <phone_ext>692225</phone_ext>
      <email>wei.zheng@zs-hospital.sh.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yi-an Zhang, M.D.</last_name>
      <phone>021-64041990</phone>
      <phone_ext>692325</phone_ext>
      <email>zhang.yi_an@zs-hospital.sh.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Zheng Wei, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yi-an Zhang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shi-yang Gu, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 23, 2021</study_first_submitted>
  <study_first_submitted_qc>November 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2021</study_first_posted>
  <last_update_submitted>November 26, 2021</last_update_submitted>
  <last_update_submitted_qc>November 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>Humans</keyword>
  <keyword>Prospective Studies</keyword>
  <keyword>Selenium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

